- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06846515
Fase 3 Evaluering av effekt og sikkerhet for AR882 hos giktpasienter (AR882-301)
En fase 3-randomisert, dobbeltblind, multisenter, placebokontrollert studie for å evaluere effektiviteten og sikkerheten til AR882 hos deltakere med gikt
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35215
- Arthrosi Investigative Site (620)
-
Huntsville, Alabama, Forente stater, 35801
- Arthrosi Investigative Site (616)
-
-
Arizona
-
Peoria, Arizona, Forente stater, 85381
- Arthrosi Investigative Site (680)
-
Phoenix, Arizona, Forente stater, 85018
- Arthrosi Investigative Site (640)
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Arthrosi Investigative Site (617)
-
-
California
-
Garden Grove, California, Forente stater, 92844
- Arthrosi Investigative Site (614)
-
La Mesa, California, Forente stater, 91942
- Arthrosi Investigative Site (618)
-
La Mesa, California, Forente stater, 91942
- Arthrosi Investigative Site (687)
-
La Palma, California, Forente stater, 90623
- Arthrosi Investigative Site (655)
-
Lincoln, California, Forente stater, 95648
- Arthrosi Investigative Site (632)
-
Lomita, California, Forente stater, 90717
- Arthrosi Investigative Site (605)
-
Long Beach, California, Forente stater, 90806
- Arthrosi Investigative Site (675)
-
Santa Monica, California, Forente stater, 90404
- Arthrosi Investigative Site (603)
-
Tarzana, California, Forente stater, 91356
- Arthrosi Investigative Site (672)
-
Thousand Oaks, California, Forente stater, 91360
- Arthrosi Investigative Site (656)
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Arthrosi Investigative Site (660)
-
Colorado Springs, Colorado, Forente stater, 80909
- Arthrosi Investigative Site (669)
-
Fort Collins, Colorado, Forente stater, 80528
- Arthrosi Investigative Site (612)
-
-
Florida
-
Cooper City, Florida, Forente stater, 33024
- Arthrosi Investigative Site (665)
-
Jupiter, Florida, Forente stater, 33458
- Arthrosi Investigative Site (613)
-
Miami, Florida, Forente stater, 33173
- Arthrosi Investigative Site (611)
-
Miami, Florida, Forente stater, 33176
- Arthrosi Investigative Site (644)
-
Palmetto Bay, Florida, Forente stater, 33157
- Arthrosi Investigative Site (694)
-
Sanford, Florida, Forente stater, 32771
- Arthrosi Investigative Site (615)
-
Tampa, Florida, Forente stater, 33609
- Arthrosi Investigative Site (600)
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- Arthrosi Investigative Site (673)
-
Marietta, Georgia, Forente stater, 30060
- Arthrosi Investigative Site (652)
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96814
- Arthrosi Investigative Site (658)
-
-
Idaho
-
Boise, Idaho, Forente stater, 83713
- Arthrosi Investigative Site (676)
-
Meridian, Idaho, Forente stater, 83642
- Arthrosi Investigative Site (634)
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60602
- Arthrosi Investigative Site (657)
-
Melrose Park, Illinois, Forente stater, 60160
- Arthrosi Investigative Site (648)
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Arthrosi Investigative Site (678)
-
-
Kansas
-
Overland Park, Kansas, Forente stater, 66209
- Arthrosi Investigative Site (679)
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40205
- Arthrosi Investigative Site (674)
-
-
Louisiana
-
Mandeville, Louisiana, Forente stater, 70471
- Arthrosi Investigative Site (627)
-
New Orleans, Louisiana, Forente stater, 70115
- Arthrosi Investigative Site (650)
-
Prairieville, Louisiana, Forente stater, 70769
- Arthrosi Investigative Site (641)
-
-
Maryland
-
Oxon Hill, Maryland, Forente stater, 20745
- Arthrosi Investigative Site (662)
-
Rockville, Maryland, Forente stater, 20852
- Arthrosi Investigative Site (653)
-
-
Massachusetts
-
Fall River, Massachusetts, Forente stater, 02721
- Arthrosi Investigative Site (636)
-
-
Michigan
-
Farmington Hills, Michigan, Forente stater, 48334
- Arthrosi Investigative Site (628)
-
Southfield, Michigan, Forente stater, 48076
- Arthrosi Investigative Site (645)
-
-
Mississippi
-
Gulfport, Mississippi, Forente stater, 39503
- Arthrosi Investigative Site (633)
-
Jackson, Mississippi, Forente stater, 39202
- Arthrosi Investigative Site (635)
-
Olive Branch, Mississippi, Forente stater, 38654
- Arthrosi Investigative Site (693)
-
-
Missouri
-
Springfield, Missouri, Forente stater, 65807
- Arthrosi Investigative Site (637)
-
Town and Country, Missouri, Forente stater, 63017
- Arthrosi Investigative Site (626)
-
-
Montana
-
Missoula, Montana, Forente stater, 59808
- Arthrosi Investigative Site (664)
-
-
Nebraska
-
Lincoln, Nebraska, Forente stater, 68516
- Arthrosi Investigative Site (610)
-
Omaha, Nebraska, Forente stater, 68114
- Arthrosi Investigative Site (684)
-
Omaha, Nebraska, Forente stater, 68144
- Arthrosi Investigative Site (651)
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89102
- Arthrosi Investigative Site (686)
-
-
New York
-
Brooklyn, New York, Forente stater, 11215
- Arthrosi Investigative Site (661)
-
Hartsdale, New York, Forente stater, 10530
- Arthrosi Investigative Site (663)
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28207
- Arthrosi Investigative Site (625)
-
Charlotte, North Carolina, Forente stater, 28277
- Arthrosi Investigative Site (681)
-
Raleigh, North Carolina, Forente stater, 27607
- Arthrosi Investigative Site (683)
-
Shelby, North Carolina, Forente stater, 28150
- Arthrosi Investigative Site (649)
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58104
- Arthrosi Investigative Site (666)
-
-
Ohio
-
Mason, Ohio, Forente stater, 45040
- Arthrosi Investigative Site (671)
-
-
Oklahoma
-
Norman, Oklahoma, Forente stater, 73072
- Arthrosi Investigative Site (631)
-
Tulsa, Oklahoma, Forente stater, 74133
- Arthrosi Investigative Site (642)
-
-
Pennsylvania
-
Horsham, Pennsylvania, Forente stater, 19044
- Arthrosi Investigative Site (647)
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Arthrosi Investigative Site (623)
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29407
- Arthrosi Investigative Site (638)
-
Fort Mill, South Carolina, Forente stater, 29707
- Arthrosi Investigative Site (604)
-
North Charleston, South Carolina, Forente stater, 29405
- Arthrosi Investigative Site (608)
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37404
- Arthrosi Investigative Site (619)
-
Hendersonville, Tennessee, Forente stater, 37075
- Arthrosi Investigative Site (624)
-
-
Texas
-
Amarillo, Texas, Forente stater, 79106
- Arthrosi Investigative Site (670)
-
Austin, Texas, Forente stater, 78735
- Arthrosi Investigative Site (677)
-
DeSoto, Texas, Forente stater, 75115
- Arthrosi Investigative Site (639)
-
Houston, Texas, Forente stater, 77074
- Arthrosi Investigative Site (601)
-
Plano, Texas, Forente stater, 75024
- Arthrosi Investigative Site (688)
-
Prosper, Texas, Forente stater, 75078
- Arthrosi Investigative Site (689)
-
Tomball, Texas, Forente stater, 77375
- Arthrosi Investigative Site (646)
-
Tomball, Texas, Forente stater, 77375
- Arthrosi Investigative Site (659)
-
-
Utah
-
Clinton, Utah, Forente stater, 84015
- Arthrosi Investigative Site (643)
-
Salt Lake City, Utah, Forente stater, 84121
- Arthrosi Investigative Site (609)
-
Salt Lake City, Utah, Forente stater, 84124
- Arthrosi Investigative Site (654)
-
-
Washington
-
Bellevue, Washington, Forente stater, 98004
- Arthrosi Investigative Site (685)
-
-
Wisconsin
-
Kenosha, Wisconsin, Forente stater, 53144
- Arthrosi Investigative Site (668)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- History of gout
- Occurrence of ≥ 2 self-reported gout flares in the last 12 months
- Body weight no less than 50 kg
- Patients who are NOT on approved urate-lowering therapy (ULT) must have sUA ≥ 7 mg/dL
- Patients who are on medically appropriate ULT must have sUA > 6 mg/dL
- Serum creatinine must be < 3.0 mg/dL and estimated CLcr ≥ 30 mL/min
Exclusion Criteria:
- Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
- Pregnant or breastfeeding
- History of symptomatic kidney stones within the past 6 months
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: AR882 50 mg
AR882 50 mg taken once daily for 12 months |
Solid Oral Capsule |
|
Eksperimentell: AR882 75 mg
AR882 75 mg taken once daily for 12 months |
Solid Oral Capsule |
|
Placebo komparator: Placebo
AR882 matching placebo taken once daily for 12 months |
Matching Solid Oral Capsule Placebo |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum urate (uric acid) (sUA) level < 6 mg/dL at month 6
Tidsramme: 24 weeks
|
Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level < 6 mg/dL at month 6 |
24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in tophus burden by month 12
Tidsramme: 48 weeks
|
Comparison of the treatment groups for the proportion of patients who experience a complete response, marked or partial response, of at least 1 target tophus at Month 12, with no evidence of disease progression (no new tophus or single tophus showing progression) and patients with no new tophi formation at month 12 as determined using the computer-assisted photographic evaluation in rheumatology (CAPER) method |
48 weeks
|
|
Serum urate (uric acid) (sUA) level < 6 mg/dL from the end of month 9 to the end of month 12
Tidsramme: 12 weeks
|
Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level < 6 mg/dL for the 3-month period from the end of month 9 to the end of month 12 |
12 weeks
|
|
Change in tophus burden by month 6
Tidsramme: 24 weeks
|
Comparison of the treatment groups for the proportion of patients who experience a complete response, marked or partial response, of at least 1 target tophus at Month 6, with no evidence of disease progression (no new tophus or single tophus showing progression) and patients with no new tophi formation at month 6 as determined using the computer-assisted photographic evaluation in rheumatology (CAPER) method |
24 weeks
|
|
Incidence of Adverse Events
Tidsramme: 56 weeks
|
Treatment Emergent Adverse Events and Serious Adverse Event incidence |
56 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Robert Keenan, MD, Arthrosi Therapeutics, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Krystallarthropatier
- Muskel- og skjelettsykdommer
- Patologiske prosesser
- Leddgikt
- Leddsykdommer
- Revmatiske sykdommer
- Purin-Pyrimidin-metabolisme, medfødte feil
- Metabolisme, medfødte feil
- Genetiske sykdommer, medfødte
- Metabolske sykdommer
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Gikt
- Hyperurikemi
- Leddgikt, gikt
Andre studie-ID-numre
- AR882-301
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .